Compare Incyte Corporation (INCY) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VanEck Rare Earth/Strategic Metals — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while VanEck Rare Earth/Strategic Metals trades at $71.5. The key difference: Incyte Corporation is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| INCY | REMX | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $109.53 |
52-Week Low | $67.38 | $49.22 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $69.85, down 3.88% over the past day amid a bearish technical signal, with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth and strategic metals companies, heavily weighted toward China, and exhibits high volatility around 50% annually. Recent news highlights rare earth metals' strategic importance in technology and energy security, with China's export controls and geopolitical tensions influencing supply dynamics.
Outlook remains speculative due to geopolitical risks and commodity price swings, offering growth potential from the reshoring of critical mineral supply chains. Key risks include China concentration, regulatory changes, and high ETF turnover, making it suitable only for aggressive portfolios as a satellite holding. Investors should weigh supply chain diversification trends against volatility and liquidity concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
